| Fedratinib studied in …STUDIED_INderived12 of 12show fewer |
|---|
| → studied in | NCT04282187Phase 2 · recruiting Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms · 12 trials list this drug (2 active) | — | — | Myelodysplastic Syndrome,Myelodysplastic/Myeloproliferative Neoplasm,Myeloproliferative Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01437787Phase 3 · terminated Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis · 12 trials list this drug (2 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01523171Phase 2 · terminated Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib · 12 trials list this drug (2 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04817007Phase 1/Phase 2 · active not recruiting A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) · 12 trials list this drug (2 active) | — | — | Primary Myelofibrosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03952039Phase 3 · completed An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib · 12 trials list this drug (2 active) | — | — | Primary Myelofibrosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01420770Phase 2 · completed Phase 2 Study of SAR302503 in Patients With Myelofibrosis · 12 trials list this drug (2 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01420783Phase 2 · completed Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia · 12 trials list this drug (2 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01585623Phase 1 · completed Drug Interaction Study of SAR302503 in Patients With Solid Tumor · 12 trials list this drug (2 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01836705Phase 1 · completed Effect of SAR302503 on ECG Activity in Patients With Solid Tumors · 12 trials list this drug (2 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03755518Phase 3 · terminated A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib · 12 trials list this drug (2 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase,Primary Myelofibrosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04955938Phase 1 · withdrawn A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms · 12 trials list this drug (2 active) | — | — | Liquid Tumor,Myeloproliferative Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05524857Phase 1 · terminated Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP) · 12 trials list this drug (2 active) | — | — | Myeloproliferative Neoplasm | 1 | Observed | clinicaltrials | graph → |